Clinical Trial: Intravitreal Conbercept for Idiopathic Choroidal Neovascularization

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Intravitreal Conbercept for Idiopathic Choroidal Neovascularization

Brief Summary: The purpose of this study is to evaluate the efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy as primary treatment for ICNV.

Detailed Summary:
Sponsor: Jiao Mingfei

Current Primary Outcome:

  • visual acuity(Snellen chart) [ Time Frame: baseline ]
  • visual acuity(Snellen chart) [ Time Frame: Change from Baseline visual acuity at one day after injection ]
  • visual acuity(Snellen chart) [ Time Frame: Change from Baseline visual acuity at one week after injection ]
  • visual acuity(Snellen chart) [ Time Frame: Change from Baseline visual acuity at four weeks after injection ]
  • visual acuity [ Time Frame: Change from Baseline visual acuity at eight weeks after injection ]
  • visual acuity(Snellen chart) [ Time Frame: Change from Baseline visual acuity at 12weeks after injection ]
  • visual acuity(Snellen chart) [ Time Frame: Change from Baseline visual acuity at half year after injection ]
  • visual acuity(Snellen chart) [ Time Frame: Change from Baseline visual acuity at 1 year after injection ]


Original Primary Outcome:

  • visual acuity [ Time Frame: baseline ]
  • visual acuity [ Time Frame: Change from Baseline visual acuity at one day after injection ]
  • visual acuity [ Time Frame: Change from Baseline visual acuity at one week after injection ]
  • visual acuity [ Time Frame: Change from Baseline visual acuity at four weeks after injection ]
  • visual acuity [ Time Frame: Change from Baseline visual acuity at eight weeks after injection ]
  • visual acuity [ Time Frame: Change from Baseline visual acuity at 12weeks after injection ]
  • visual acuity [ Time Frame: Change from Baseline visual acuity at half year after injection ]
  • visual acuity [ Time Frame: Change from Baseline visual acuity at 1 year after injection ]


Current Secondary Outcome:

  • macular central fovea thickness(OCT) [ Time Frame: baseline ]
  • macular central fovea thickness [ Time Frame: Change from Baseline macular central fovea thickness at four weeks after injection ]
  • macular central fovea thickness(OCT) [ Time Frame: Change from Baseline macular central fovea thickness at eight weeks after injection ]
  • macular central fovea thickness(OCT) [ Time Frame: Change from Baseline macular central fovea thickness at 12 weeks after injection ]
  • macular central fovea thickness(OCT) [ Time Frame: Change from Baseline macular central fovea thickness at half year after injection ]
  • macular central fovea thickness(OCT) [ Time Frame: Change from Baseline macular central fovea thickness at 1 year after injection ]


Original Secondary Outcome:

  • macular central fovea thickness [ Time Frame: baseline ]
  • macular central fovea thickness [ Time Frame: Change from Baseline macular central fovea thickness at four weeks after injection ]
  • macular central fovea thickness [ Time Frame: Change from Baseline macular central fovea thickness at eight weeks after injection ]
  • macular central fovea thickness [ Time Frame: Change from Baseline macular central fovea thickness at 12 weeks after injection ]
  • macular central fovea thickness [ Time Frame: Change from Baseline macular central fovea thickness at half year after injection ]
  • macular central fovea thickness [ Time Frame: Change from Baseline macular central fovea thickness at 1 year after injection ]


Information By: Tianjin Medical University Eye Hospital

Dates:
Date Received: July 27, 2016
Date Started: June 2016
Date Completion:
Last Updated: August 9, 2016
Last Verified: August 2016